Sugi Predict

Sugi Predict / Targets / MAP3K10

MAP3K10

Mitogen-activated protein kinase kinase kinase 10 · Q02779 · MAP3K10 on Sugi Atlas →

4,690 patent compounds predicted against MAP3K10, 3,646 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5964631 SCHEMBL5964631 0.86 8/20
SCHEMBL1649555 SCHEMBL1649555 0.67 7/20
SCHEMBL2755778 SCHEMBL2755778 0.61 6/20
K-252A K-252A (SCHEMBL968886) 1.00 4/20
K-252A K-252A (SCHEMBL1982253) 1.00 4/20
SCHEMBL3072275 SCHEMBL3072275 1.00 4/20
SCHEMBL3082217 SCHEMBL3082217 1.00 4/20
SCHEMBL3075228 SCHEMBL3075228 0.80 4/20
SCHEMBL5951557 SCHEMBL5951557 0.77 4/20
SCHEMBL3264416 SCHEMBL3264416 0.65 4/20
SCHEMBL2466653 SCHEMBL2466653 0.61 4/20
SCHEMBL5173554 SCHEMBL5173554 0.61 4/20
SCHEMBL3268039 SCHEMBL3268039 0.76 3/20
SCHEMBL6627054 SCHEMBL6627054 0.76 3/20
SCHEMBL6627111 SCHEMBL6627111 0.76 3/20
SCHEMBL6628462 SCHEMBL6628462 0.76 3/20
SCHEMBL6628810 SCHEMBL6628810 0.76 3/20
SCHEMBL6629443 SCHEMBL6629443 0.76 3/20
SCHEMBL6629555 SCHEMBL6629555 0.76 3/20
SCHEMBL6629697 SCHEMBL6629697 0.74 3/20

Clinical trials — most relevant to MAP3K10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility. PHASE3UNKNOWN
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer PHASE1/PHASE2WITHDRAWN
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy nanUNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAP3K10 binder may also engage these)

ProteinNameSimilarity
D3ZG83 — 1.000 D3ZG83 →
Q66L42 — 1.000 Q66L42 →
Q80XI6 — 1.000 Q80XI6 →
Q66HA1 — 1.000 Q66HA1 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.999 landscape →
Q3U1V8 — 0.994 Q3U1V8 →
MAP3K11 Mitogen-activated protein kinase kinase kinase 11 0.993 landscape →
Q8VDG6 — 0.993 Q8VDG6 →
Q60700 — 0.993 Q60700 →
Q5BJT1 — 0.992 Q5BJT1 →
LMTK3 Serine/threonine-protein kinase LMTK3 0.992 landscape →
MAP3K21 Mitogen-activated protein kinase kinase kinase 21 0.992 landscape →
O70405 — 0.992 O70405 →
A2AEV7 — 0.991 A2AEV7 →
A2A699 — 0.991 A2A699 →
Q69YU3 — 0.990 Q69YU3 →
O54967 — 0.990 O54967 →
P58660 — 0.990 P58660 →
Q86YV0 — 0.990 Q86YV0 →
Q96FS4 — 0.989 Q96FS4 →
Q9P1Y5 — 0.989 Q9P1Y5 →
Q9BZL4 — 0.989 Q9BZL4 →
TESK1 Dual specificity testis-specific protein kinase 1 0.989 landscape →
Q8BLS7 — 0.989 Q8BLS7 →
Q6ZUM4 — 0.989 Q6ZUM4 →
Q7TN12 — 0.988 Q7TN12 →
Q8JZP9 — 0.988 Q8JZP9 →
Q9Y4B5 — 0.988 Q9Y4B5 →
A5PKJ4 — 0.988 A5PKJ4 →
Q53LP3 — 0.988 Q53LP3 →